Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

BACKGROUND: This study evaluated outcomes among patients with advanced/metastatic non-small-cell lung cancer (NSCLC) treated at Asian centers participating in the global named-patient-use (NPU) program for afatinib. METHODS: Patients had progressed after initial benefit with erlotinib or gefitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Gee-Chen, Lam, David Chi-Leung, Tsai, Chun-Ming, Chen, Yuh-Min, Shih, Jin-Yuan, Aggarwal, Shyam, Wang, Shuhang, Kim, Sang-We, Kim, Young-Chul, Wahid, Ibrahim, Li, Rubi, Lim, Darren Wan-Teck, Sriuranpong, Virote, Chan, Raymond Tsz-Tong, Lorence, Robert M., Carriere, Philippe, Raabe, Christina, Cseh, Agnieszka, Park, Keunchil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055616/
https://www.ncbi.nlm.nih.gov/pubmed/33783657
http://dx.doi.org/10.1007/s10147-021-01869-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055616/
https://www.ncbi.nlm.nih.gov/pubmed/33783657
http://dx.doi.org/10.1007/s10147-021-01869-0

Ejemplares similares